Safety Alerts & Recalls
What does this mean?
Vibativ (telavancin) is a new antibiotic only used in hospitals for very specific infections. If you have been prescribed Vibativ your healthcare professionals will have taken relevant prescribing advice into account to maintain a favourable balance of benefit to risk. If you have any questions about the contents of this alert or your treatment with Vibativ you should speak to your doctor or other healthcare professional.
Clinigen Advises Healthcare Professionals About Vibativ Safety Concerns
Clinigen has written to healthcare professionals to advise them about safety concerns associated with the use of Vibativ (telavancin) and how to minimise the risk to patients. Vibativ should not be used to treat complicated skin and soft tissue infections or other non-approved conditions. Vibativ should not be used in patients with severely impaired kidney function, and all patients prescribed Vibativ should have their kidney function monitored for at least the first 3-5 days of therapy and every 48-72 hours thereafter. Because it can affect heart rhythm, prescribers are advised to use caution when giving Vibativ at the same time as other medicines that affect heart rhythm and to patients at high risk of abnormal heart rhythm. Vibativ should not be used during pregnancy and a negative pregnancy test must be recorded before it is prescribed to women of childbearing potential.
Vibativ, contains the medication telavancin and is a new antibiotic given by intravenous infusion for the treatment of pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA).
For more information please visit: more information here